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Missense mutations in TP53 gene promote metastasis in human tumours. However, little is known about
the complete loss of function of p53 in tumour metastasis. Here we show that squamous cell carcinomas
generatedbythespecific ablationofTrp53geneinmouseepidermisarehighlymetastatic.Biochemical and
genome-wide mRNA and miRNA analyses demonstrated that metastases are associated with the early
induction of epithelial-mesenchymal transition (EMT) and deregulated miRNA expression in primary
tumours. Increased expression of miR-21 was observed in undifferentiated, prometastatic mouse tumours
and in human tumours characterized by p53 mutations and distant metastasis. The augmented expression
ofmiR-21,mediatedbyactivemTORandStat3signalling,conferredincreasedinvasivepropertiestomouse
keratinocytes in vitro and in vivo, whereas blockade of miR-21 in a metastatic spindle cell line inhibits
metastasis development. Collectively these data identify novel molecular mechanisms leading to metastasis
in vivo originated by p53 loss in epithelia.
T
umour metastasis is the major cause of mortality of human cancers. In epithelial tumours, metastasis is
frequently associated with the loss of epithelial characteristics and the acquisition of mesenchymal prop-
erties by a genetically controlled process named epithelial mesenchymal transition (EMT), which is also
essentialduringembryonicdevelopment
1,2.Thesefactshaveposedtremendouseffortstounderstandthemolecu-
lar mechanism governing EMT in order to find possible therapeutic agents that impair metastatic growth of the
tumours. A number of master genes controlling EMT in tumors have been identified
2. Importantly, EMT is also
related to cancer cell stemness
3, and the presence of these putative cancer stem cells is associated with metastatic
spreading
4,5.
The p53 tumour suppressor coordinates the cellular response to stress, including DNA damage, hypoxia, and
oncogenic stress through transcriptional mechanisms, resulting in cell cycle arrest, senescence, or apoptosis.
Accordingly, p53 mutations are widely involved in human tumourigenesis
6 and are also associated with poor
prognosis and high metastatic potential in human tumours
6,7. Recently, several groups have demonstrated that
missense, gain of function-associated mutations in TP53 gene, promote tumour metastasis by interfering with
integrin and TGFb signalling
8,9. However, little is known about the molecular mechanisms of metastasis due to
complete loss of function of p53. Indeed, observations based on mouse knock out models have led to the
assumption that complete p53 loss is not prone to metastasis
10, unless other members of the p53 family are also
ablated
11. However, gene mutation analyses of human cancer clinical samples revealed that loss of p53 is also
frequent in metastatic tumours, although the molecular mechanisms involved are not defined.
MicroRNAs (miRNAs) are a recently discovered class of small RNA molecules that negatively regulate gene
expression at the post-transcriptional level. As some of these genes are involved in the control of development,
proliferation, apoptosis, and stress response, it is not surprising that deregulated expression of miRNAs is
implicated in tumor development. Importantly, miRNAs have been associated with metastatic spreading,
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12-
14. Recent evidences have also linked the p53 tumor suppressor with
the altered expression or maturation of miRNAs
15-18.
We andothers havepreviously described thatthe specific ablation
of Trp53 gene in stratified epithelia (hereafter p53
DEC) leads to spon-
taneous squamous cell carcinomas (SCC) development
19,20. Tumor
development is associated to premature chromosome instability
21
and is accelerated by the epidermal ablation of Rb1 gene (hereafter
Rb
DEC). This last aspect is due to the increased proliferation, pro-
moted by pRb loss, in conjunction with activation of specific signal
transduction mechanisms
20,21. Such cooperative functions can also
explain the findings obtained in Rb
DEC mice. These Rb
DEC mice
showed altered differentiation and increased proliferation in epi-
dermis,butdidnotdevelopspontaneoustumours
22.Moreover,upon
chemical carcinogenesis protocols Rb
DEC mice exhibited reduced
tumour susceptibility, although the tumors displayed more malig-
nant characteristics due to premature p53 loss
23,24. The relationship
between pRb and p53 in epithelial cells is also supported by Rb
DEC;
p107-/-mousemodels,whicharepronetooncogenictransformation
due, in part, to the impairment of p53 proapoptotic functions
25.
GeneexpressionanalysisofoverttumoursarisinginRb
DEC;p53
DEC
and p53
DEC mice revealed no significant differences between the two
genotypes
26, indicating that cooperation is only evidenced at early
stages of tumor development
20. The majority of genes overexpressed
intumoursareinvolvedincellcycleand,inparticular,inmitosis
26,in
agreement with the described altered chromosome instability
mediated by the epidermal loss of p53
21. These genomic profiling
studies also revealed a highly significant overlap with stem cell
signatures and evidences of EMT processes, and demonstrated that
these mouse tumours share relevant characteristics with multiple
human malignancies distinguished by poor prognosis, altered p53
status and, remarkably, high metastasis incidence
26. These data
prompted us to analyze the possible metastatic capacities of spon-
taneous tumours arising in Rb
DEC; p53
DEC and p53
DEC mice. Here we
show that these epidermal tumours are highly prone to form lung
metastasis in association with an early development of EMT genetic
program.Inaddition,wealsoobservedthatprimarytumoursleading
to lung metastasis displayed deregulated expression of specific
miRNAs, including miR-21. Overexpression and blockade experi-
ments demonstrated not only the involvement of miR-21 in EMT,
but also its specific implication in tumour aggressiveness and meta-
staticspreading.Collectively,ourfindingsindicatethattargetedther-
apies aimed to restore the affected pathways and/or modulate
miRNA expression would be of great benefit in the treatment of
tumours bearing altered p53 functions, in particular those bearing
truncated p53 mutations.
Results
Trp53-deficient epidermal tumors are metastatic. To analyze the
metastaticpotentialofspontaneoustumoursfromRb
DEC;p53
DECand
p53
DEC mice, a full necropsy analysis was performed in mice bearing
primary tumors. We found that a high proportion of these mice
displayed lung metastases, in some cases macroscopically
detectable (Fig 1a). Moreover, upon histology studies we found
that a large number of mice displaying primary epidermal tumours
also exhibited the presence of small cell masses in the lungs (Fig 1b).
The expression of epidermal keratin K5 in these lesions (Fig 1b’),
together with the absence of similar events in mice without primary
epidermal tumours, and the absence of recombination of Rb1 or
Trp53 genes in lungs (not shown), strongly suggested that these
tumours were metastasis derived from epidermal primary tu-
mours. The metastases were also detected by PET studies by 30-50
Figure 1 | Spontaneoustumours inRb
DEC;p53
DECandp53
DECmicearemetastasic. (a)Exampleofalungshowingmacroscopic metastases(redarrows).
(b)H&Eand(b’)antiK5stainedsectionfromalungshowingmicrometastaticoutgrowthspositivefortheepidermalmarkerkeratinK5.(c)Examplesof
invivoimagingusingPETatdays0,20and40afterdetectionoftwoprimarytumoursintheneckarea(whitearrows).Notethepresenceofsmallpositive
areas in the lungs (small orange arrows) 40 days after the detection of the primary tumours. Kaplan Meier distribution of primary tumour (d) and
metastasis (d’) in Rb
DEC; p53
DEC (.) and p53
DEC (#) mouse cohorts. p values correspond to Log-Rank test. Distribution of metastasis incidence (mice
bearing metastasis with respect to total number of mice with primary tumors) according to the mouse genotype (e) or the differentiation status of the
primary tumor type (e’).
www.nature.com/scientificreports
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alsoevidencedbyanalyzingcohortsofRb
DEC;p53
DECandp53
DECmice
(Fig 1d, d’). Overall, 50-65% of the mice that displayed primary
epidermal tumours also showed metastatic outgrowths in the
lungs. These studies also indicated that, similarly to the primary
tumours (Fig 1d), in Rb
DEC; p53
DEC mice metastases occurred
earlier than in p53
DEC mice (Fig 1d’). However, the metastasis rate
was similar in both groups (Fig 1e). On the other hand, when the
metastasisratewasrelatedtothehistologyoftheprimarytumour,we
observed increased metastasis incidence in mice bearing spindle cell
carcinomas (SpCCs) compared to squamous cell carcinomas (SCCs)
(Fig 1e’). These results demonstrated that p53-deficient epidermal
tumours (both Rb
DEC; p53
DEC and p53
DEC) are highly metastatic, and
the metastasis are more frequent when primary tumours display
spindle undifferentiated phenotype.
Trp53-deficient epidermal tumors undergo EMT. The gene
expression profile of primary tumours arising in Rb
DEC; p53
DEC and
p53
DEC mice suggested that SpCCs underwent EMT
26. Indeed in
supervised hierarchical clustering aimed to discriminate between
Rb
DEC; p53
DEC and p53
DEC tumours, the metastatic primary tumors
(denoted by arrows in Fig 2a) did not cluster together. On the
contrary, when a recently developed EMT signature
27 was applied
to the microarray data in unsupervised clustering metastatic tumors
are grouped together (Fig 2b). We thus studied the possible EMT
events in SCCs and SpCCs arising in Rb
DEC; p53
DEC and p53
DEC mice.
In agreement with the spindle morphology, we observed decreased
E-cadherin(Fig2c,c’)andincreasedvimentin(Fig2d,d’)expression
inSpCCs.SincegeneexpressiondatarevealedthattheSpCCshowed
increased expression of essential transcriptional modulators of
EMT process
26, we also studied their expression by immunohis-
tochemistry. We observed expression of Twist, Snail and FoxC2
(Fig 2e-g’) in SCCs and in SpCCs. However, in SCCs their
expression occurred prior to overt EMT process in migrating cells
and more undifferentiated areas of squamous tumours (Fig 2e, f, g),
whilst inSpCCs(Fig 2e’, f’, g’)we observed generalized expression of
Figure 2 | PrimarytumorsinRb
DEC;p53
DECandp53
DECmiceundergoEMT. (a-b)Hierarchicalclusteringofmousetumorsandnormalskinshowingthe
discrimination between genotypes (a) and according to an EMT gene signature (b). Note that metastatic tumours (denoted by arrows) cluster together
only in the second case. c-g’) Examples of spontaneous squamous (c, d, e, f, g) and spindle cell carcinoma (c’, d’, e’, f’, g’) showing the expression of E-
Cadherin (c, c’), Vimentin (d, d’), Twist (e, e’), Snail (f, f’) and FoxC2 (g, g’). Dashed lines in c-g denote the boundaries between differentiated and
undifferentiated areas in squamous tumours. Bars 5 150 mm. (h) Western blot showing the expression of the quoted EMT markers and modulators in
skin,squamousandspindlecellcarcinomas.i)qRT-PCRanalysisshowingtheexpressionofSnai1geneintumoursaccordingthemousegenotype(upper
panel), metastatic behaviour (middle Panel) and tumour differentiation characteristics (lower panel) n5 number of tumours analysed.
www.nature.com/scientificreports
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showed increased expression of Snail, FoxC2, Twist and Zeb1 in
SpCC compared to SCCs, in parallel with decreased E-Cadherin
and increased Vimentin expression (Fig 2h). Finally, qRT-PCR
studies showed that increased expression was found in primary
tumours originating metastasis, and in SpCC compared to SCCs
(Fig 2i), although no major differences in Snai1 gene expression
levels between Rb
DEC; p53
DEC and p53
DEC tumours.
Deregulated miRNA expression in metastasic mouse epidermal
tumors. Recent findings have demonstrated that deregulated
expression of specific miRNAs controls EMT and metastasis
28-30,
and is involved in TGFb signalling pathway
31. We thus in-
vestigated whether deregulated miRNA expression could also
contribute to spontaneous tumor development and metastasis in
Rb
DEC; p53
DEC and p53
DEC mice. Microarray analysis showed that
210 different miRNA species (448 probes) could discriminate
between epidermis and tumors (Fig 3a and Supp Table 1). This set
ofselectedmiRNAsshowedbothincreasedanddecreasedexpression
compared to normal skin, and included several species previously
found to be expressed in epidermis
32,33 and different miRNAs
previously involved in metastasis
34,35. In agreement with the
increased expression of multiple miRNA in tumours, we found
only few tumor samples showing decreased expression of miRNA
processing proteins Dicer, Dgcr8 or Drosha compared to normal
samples (Supp Fig 1a), suggesting that the observed changes are
not attributable to impaired miRNA processing, as reported in
other tumour types
36,37.
In this microarray analysis the metastatic tumours are not clus-
tered (denoted by arrows in Fig 3a). To identify possible miRNAs
involved in metastasis, the whole selected set of 448 probes was used
to discriminate non tumoural skin, squamous and spindle cell carci-
nomas by supervised clustering. This analysis rendered 14 probes
corresponding to miR-23, miR-29*, miR-19a, miR-21, miR-105 and
miR-135b discriminating metastatic and non-metastatic primary
tumors (Fig 3b). Of note, although qRT-PCR analyses showed no
significant differences between SCCs and SpCCs respect to miRNAs
regulated by p53 family or those belonging to the miR-200 family
(SuppFig1b),theoverallexpressionofmiR-200familymemberswas
decreased in SpCCs compared to SCCs (Fig 3c). Additionally, to
further support the miRNA microarray analyses, we used the
gene expression microarray data to monitor the expression of genes
predicted to be targets of miR-21, miR-29 and miR-105 (using
miRgen
38) in unsupervised manner. In all the cases (Supp Fig 1c, d,
Figure 3 | AlteredmiRNAexpressioninp53-deficientspontaneoustumors. (a,b)HierarchicalclusteringofmiRNAshowingthedifferentialexpression
discriminating between normal skin and mouse tumours (a), and discriminating normal skin, squamous and spindle tumours (b). (c) Box plot showing
the overall expression of miR-200 family of miRNAs between squamous and spindle tumours obtained by qRT-PCR. (d) Box plots showing the
expression of miR-21 in metastatic and non metastatic mouse tumours (upper panel), in tumours from Rb
DEC; p53
DEC and p53
DEC mice (middle panel),
and spindle and squamous cell carcinomas (lower panel) n5 number of tumours analysed. e-h9) Immunohistochemistry examples showing the
expression of Sprouty2 (e, e9), phosphorylated Erk (f, f9), PTEN (g, g9) and phosphorylated Akt (h, h9) in squamous cell carcinomas (e, f, g, h) and in
spindle cell tumours (e9,f 9,g 9,h 9). i) Western blot analysis of squamous, spindle and mixed tumours (tumours showing areas of squamous and spindle
cell morphology) showing reduced expression of PTEN and Sprouty 2 in undifferentiated samples in parallel with increased expression of Zeb1 and
phosphorylation of Akt and Erk. (j) Quantitative RTPCR analysis of the expression of miR-21 in the same tumor samples used in i.
www.nature.com/scientificreports
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forcing the relevance of these miRNAs in the process.
Given its widely reported involvement in multiple oncogenic pro-
cesses including metastasis
39, we focused our subsequent studies on
miR-21. The upregulation of mature miR-21 expression, confirmed
byqRT-PCRanalysis,wasobservedinanindependentsetofprimary
tumoursinassociationwithmetastasis,andspindlemorphology,but
not with the genotype of the tumour (Fig 3d).
The miR-21 is known to target and down-regulate the expression
of multiple tumor suppressors such as Sprouty2 (Spry2)
40 and
Pten
41,42, which lead to the upregulation of Erk/MAPK and PI3K/
Aktaxisrespectively.Insquamouscellcarcinomas,theexpressionof
Spry2andPtenwasexclusivelyfoundinthemoredifferentiatedareas
(Fig3e,g),beingalmostundetectableinspindletumours(Fig3e’,g’).
Accordingly, reduced expression of phosphorylated, active Akt and
Erk was observed in SCC (Fig 3f, h), whilst in SpCC generalized
expression of phosphorylated Akt and Erk was detected (Fig 3f’,
h’). Biochemical analysis by western blot (Fig 3i) and qRT-PCR
(Fig 3j) of different tumour samples corresponding to SCCs,
SpCCs and tumours that histologically showed a mixture of both
phenotypes, demonstrated a clear correlation between decreased
Pten and Spry2 expression, activation of Akt and Erk (Fig 3i) and
increased miR-21 (Fig 3j) expression in undifferentiated tumors.
miR-21 expression confers tumour aggressiveness and metastatic
potential. To further confirm the possible role of miR-21 in EMT
and metastasis, we first monitored the effect of increased miR-21
expression in the immortalized HaCaT keratinocyte cell line by
transfection experiments. The increased expression of miR-21
(Supp Fig 2a) did not affect the cell morphology (Supp Fig 2b, b’),
in spite of reducing Spry2 and Pten expression with a concomitant
increaseinAktandErkphosphorylation(SuppFig2c).Furthermore,
no significant changes were detected in the expression of Snail,
FoxC2 or Twist (Supp Fig 2c), and neither decrease of E-cadherin
nor increase in Vimentin were observed in transfected cells
compared with controls (Supp Fig 2d, d’, e, e’). These results
indicate that the augmented expression of miR-21 is insufficient to
drive EMT in non-transformed cells.
Next, we explored whether the increased expression of miR-21
conferred more aggressive properties to the PB mouse transformed
keratinocyte cell line. These cells are derived from a chemically
induced mouse skin papilloma
43 and develop well differentiated
SCC upon subcutaneous injection into nude mice flanks
44.
Remarkably, the overexpression of Akt in these cells conferred more
aggressive characteristics demonstrated by reduced tumour differ-
entiation, increased angiogenesis andactivation of specific biochem-
icalpathways
44-46.Inaddition, wealsogenerated cells overexpressing
Snail and both Snail and miR-21, for comparison. Transfection of
Snail in PB cells (Fig 4a) produced a moderate increase in miR-21
expression (Fig 4b), below the levels obtained upon co-transfection
of miR-21 and Snail. On the other hand, the forced expression of
miR-21, even though not reaching the levels observed in undiffer-
entiatedmousetumours,wasabletoinduceSnai1expression(Fig4a,
g). Next, we explored the effects of the different transfections in the
expression and localization of the epidermal markers keratin K5 and
E-cadherin by immunofluorescence. The data revealed that express-
ion of miR-21 (Fig 4d), Snail (Fig 4e), or co-expression of Snail and
miR-21 (Fig 4f), reduced the levels of these two proteins in cultured
cells compared with control (Fig 4c). Biochemical analyses by west-
ern blot (Fig 4g) corroborated the immunofluorescence findings on
E-cadherin downregulation, although the effects were more evident
upon expression of Snail (Fig 4g). In addition, western blot also
showed that miR-21 promoted a moderate increase in vimentin,
Snail and very mild in Foxc2, when compared to cells transfected
with Snail or Snail and miR-21 (Fig 4g). On the contrary, the induc-
tionofTwist,thedecreaseinPtenandSpry2andtheactivationofAkt
and ERK were similar in cells transfected with Snail, miR-21 and
Snail, or miR-21 alone (Fig 4g). These data indicate that miR-21 can
be sufficient to drive some characteristics of EMT, and that miR-21
can cooperate with Snail in the process.
Since EMT affects the migratory and invasive potential of trans-
formed epidermal cells, we monitored these properties in cells
expressing the above commented constructs in vitro. Our data
(Fig 4h) demonstrated that the expression of miR-21 or Snail
increased the migratory and invasive properties of PB keratinocytes.
However, the co-expression of miR-21 and Snail did not further
increase migration and invasion (Fig 4h).
NextweexploredwhetherthemiR-21mediatedchangesobserved
invitrocouldalsoaffectthetumourigenicpropertiesofthePBcellsin
vivouponsubcutaneousinjectioninnudemice.Althoughwedidnot
observe a significant difference in the appearance or growth rate of
tumours between PBmir-21 and PBmirVec cells (not shown), we
found that the expression of miR-21 dramatically changed the his-
topathology of the tumors, from a welldifferentiated SCC character-
istics (Fig 4i, j) to a more undifferentiated with SpCC morphology
(Fig 4i’, j). Further, mice injected with PBmiR-21 cells, but not those
bearing PBmiRVec cells, showed metastatic signs in the proximal
ganglia and in the lungs (3 out of 5 and 0 out of 5 injected mice,
respectively).Collectivelythesedatademonstratethattheexpression
of miR-21 conferred increased aggressiveness and metastatic prop-
erties to tumour keratinocytes.
miR-21 expression is required for metastasis in Trp53-deficient
tumor cells. The above described results indicate that miR-21
contributes to EMT and metastasis. To analyze whether these
processes are dependent on miR-21 in fully transformed cells, we
established a cell line (named 940T) from a spontaneous primary
SpCC from a Rb
DEC; p53
DEC mouse with lung metastasis. The
blockade of miR-21 in these cells using miR-ZIP-21 constructs
(Fig 5a) produced increased expression of Spry2 and Pten and the
concomitant reduced activation of Erk and Akt (Fig 5b). This also
resulted in increased E-cadherin expression (Fig 5b, c, c’) and
reduced proliferation in vitro (Fig 5d). The blockade on miR-21 in
the Rb
DEC; p53
DEC tumour derived cells also resulted in reduced
migration and invasiveness in vitro (Fig 5e).
Of note, the subcutaneous injection of miR-ZIPVec or miR-ZIP-
21 transfected cells in immunodeficient mice did not produce major
changes in tumour aggressiveness or histopathology (not shown),
although a partial reduction in tumour growth was detected at early
stages (Fig 5f). Finally, we monitored whether the miR-21 blockade
couldaffectmetastaticbehaviourofhighlytransformedcells.Tothis,
miR-ZIPVec or miR-ZIP-21 cells were injected in the tail vein and
the formation of lung metastasis was analyzed. We observed that, in
contrast with the control cells (Fig 5g) that produced the develop-
mentofalargenumberoflungmetastasis(48610perlung)inallthe
injected animals (8/8), miR-ZIP-21 transfected cells only produced
one small micrometastasis in one of the injected mice (1/8). These
resultsclearlydemonstratedthatmiR-21isnecessarytoconfermeta-
static behaviour to p53-deficient mouse skin tumours.
miR-21 expression depends on mTOR and Stat3 activity.
Numerous reports have indicated that p53 can modulate miRNA
expression
17,47,48. However, miR-21 has not been reported to be
transcriptionally modulated by p53. Thus it is conceivable that the
observed miR-21 increased expression in p53-deficient tumours is
attributable to a signalling pathway induced by p53 loss. Among
them, mTOR and Stat3 are induced by p53 deficiency
49-52 and can
modulate miR-21 expression
53-55. We thus analyzed the possible
correlation of mTOR and Stat3 activity and miR-21 expression in a
series of spontaneous tumours derived from p53
DEC and Rb
DEC;
p53
DEC mice. We found that the increased activity of mTOR,
analyzed by phosphorylated S6 ribosomal protein, and active
Stat3, determined by tyrosine-phophorylated Stat3, were found
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 2 : 434 | DOI: 10.1038/srep00434 5Figure 4 | miR-21 expression promotes invasive properties in tumor keratinocytes. (a, b) Summary of qRT-PCR analyses showing the expression of
Snai1 gene (a) and miR-21 (b) in PB keratinocytes and their derivatives upon transfection with the quoted coding plasmids. c-f) Immunofluorescence
examples showing the expression of E-cadherin (red) and keratin K5 (green) in PB cells (c) or derivatives transfected with miR-21 (d), Snail (e), or co-
transfected withSnailandmiR-21 (f).(g)Western blotanalysis showingthe expression ofthe quotedproteinsinPBcells andtransfected derivatives. (h)
Quantitative analysis using boyden chamber assays ofthe migratory (left panel), invasive (mid panel) capacities andpercentage ofinvasion (right panel)
of parental PB keratinocytes or transfected derivatives (* denotes p # 0.05; ** denotes p # 0.01). i, i’) Examples of tumours (H&E staining) produced
uponsubcutaneousinjectionofmirVec(emptyvector;i)ormiR-21transfectedPBkeratinocytes;(j)summaryofthedifferentphenotypesofthetumours
upon subcutaneous injection (n58 in each case). k) Example of lung metastasis (H&E) observed in mice bearing subcutaneous injection of tumours in
miR-21 transfected PB tumour keratinocytes. Inset shows a higher magnification of the metastasis.
www.nature.com/scientificreports
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miR-21 expression (Fig 6b). We thus used the tumour derived 940T
cell line to analyze the effects of mTOR and Stat3 signalling
inhibitors. Compared with an immortalized mouse keratinocyte
cell line (CoCa
56), the levels of miR-21 were significantly
upregulated in 940T cells (Fig 6c). These upregulated levels were
decreased by the treatment with mTOR or Stat3 inhibitors, and
significantly dropped by the combined treatment of 940T cells
with both inhibitors.
miR-21 expression is increased in human metastatic lung cancer.
Theaboveexplainedresultspromptedustoanalyzeifsimilarprocess
could also take place in human cancer samples. We have previously
demonstrated that p53
DEC and Rb
DEC; p53
DEC derived tumours
displayed a significant overlap with multiple human tumours
characterized by augmented aggressiveness and metastatic deve-
lopment
26. These included multiple epithelial cancers from
different tissues of origin, such as breast and lung
26. In particular,
we observed that in non small cell lung cancer (NSCLC) a 20-gene
signature derived from mouse p53-deficient tumours
26, can stratify
human patients and predict overall survival from a external dataset
of human lung adenocarcinoma samples (Supp Fig 3A)
57. Moreover
miR-21 has been considered an oncogene in human lung cancer
58-60.
In agreement, in two external datasets of lung cancer
61,62 the
increased expression of miR-21 is also predictive of overall survival
(Supp Fig 3b, c).
These connections prompted us to analyze whether the findings
relative to miR-21 in mouse samples could be extensive to human
lung cancers. To this, we studied the expression of miR-21 in a set of
human lung tumours of known p53 status as well as other clinical
and molecular characteristics, including gene expression profiling
63.
WeobservedasignificantassociationbetweenincreasedmiR-21and
Figure 5 | miR-21 blockade inhibits metastasis development. (a) qRT-PCR analysis showing the expression levels of miR-21 and the reporter marker
(COP-GFP) in 940T tumor cells transfected with miR ZIPVec (empty vector) or miR-ZIP-21. (b) Western blot analysis showing the expression of the
quotedproteinsinmiRZIPVecandmiR-ZIP21-transfected940Ttumorkeratinocytes.c,c’)ImmunofluorescenceexamplesshowingtheexpressionofE-
cadherin (red) in miR-ZIPVec (c) and miR-ZIP-21-transfected (c’) 940T tumour keratinocytes. (d) Immunofluorescence examples and summary of
three independent experiments showing BrdU incorporation in miR-ZIPVec and miR-ZIP-21-transfected 940T tumor keratinocytes. Bar5 25 mm. (e)
Quantitative analysis using boyden chamber assays of the migratory (upper panel), invasive (mid panel) capacities and percentage of invasion (lower
panel) of miR-ZIPVec and miR-ZIP-21-transfected 940T tumour keratinocytes. (f) Growth of tumours produced by subcutaneous injection of miR-
ZIPVec(blacksquares)andmiR-ZIP-21-transfected(redcircles)940Ttumourkeratinocytes(n56).g,g’)Examplesoflungsections(H&Estained)upon
intravenous injection of miR-ZIPVec (g’) and miR-ZIP-21-transfected (g’) 940T tumour keratinocytes. Bar51 cm.
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 2 : 434 | DOI: 10.1038/srep00434 7Figure 6 | TheexpressionofmiR-21ismodulatedbymTORandStat3inspontaneoustumors. (a)Western blot showing the expressionof phosphorylated
S6, phosphorylated Stat3 and phosphorylated Akt in skin and tumours samples of the quoted genotype and phenotype. (b) qRT-PCR showing the expression
levels of miR21 in the same tumors showed in a. (c) qRT-PCR analysis of miR-21 expression levels in non-transformed mouse immortalized keratinocytes
(CoCa) and in 940T tumour keratinocytes untreated or treated with the quoted inhibitors for 48h.
www.nature.com/scientificreports
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mutations (Fig 7b). Notably, there was a significant association
between such increased miR-21 levels and the presence of distant
metastasis in these human tumours (Fig 7c) and a significant cor-
relation between miR-21 and the expression levels of human SPRY2
and PTEN genes (Fig 7d).
Discussion
The tumour suppressor p53, plays a pivotal role in the onset and
developmentofawidelyrangeofhumancancersaffectingmorethan
50%ofhumanpatients.Thismakesthep53pathwayoneofthemain
andmostsignificanttargetsforthechemotherapeuticdrugdesign.In
mostcases,p53mutationsaremissense,whichhavebeenconsidered
toprovideagainoffunction,conferringamoreaggressivebehaviour
tothetumours.Thisis,inpart,exemplifiedbyknockoutmodels:p53
deficient mice display a restricted pattern of tumors and they are
rarelymetastatic,whereasknockinmodelsreproducinghumanmis-
sense mutants display broader types of tumours and metastasis
10.
However, truncating mutations in TP53, leading to complete loss
of p53, are profuse in certain aggressive human tumours, such in
breast cancer bearing mutated BRCA1 gene
64.
In multiple solid tumours, metastasis is preceded by EMT events,
which allow the cells to repress epithelial characteristics acquiring
mesenchymal ones and conferring migratory and invasive prop-
erties
65. We have characterized a close association of such EMT
events and the metastatic properties in our mouse models. Indeed,
we found that metastatic potential is increased in tumours that have
undergone EMT processes. The molecular events that govern the
process are similar in our and in other reported models and lie on
an aberrant TGFb signalling that leads to the expression of master
regulatory genes such as Snai1, Twist, Zeb1, Zeb2 and FoxC2
2. The
connection between EMT and p53 has been widely reported and has
been attributed to multiple signalling pathways, such as crosstalk
with Smads
66,67. Remarkably this may help to explain the poor pro-
gnosisdisplayedbyp53mutanttumours
6,7.Morerecentlyithasbeen
shown that p53 interferes with EMT processes through specific
miRNA expression, in particular by the induction of miR-34 or
miR-200 families
68-70. Of note, in our microarray experiments miR-
34 did not discriminate between control and tumour samples,
probably due to a reduced expression of this miRNA in normal skin
samples (Supp Fig 1 and data not shown). On the other hand,
although no unique miR-200 family member discriminated between
SCCand SpCC (Supp Fig1), the overall expression of thesemiRNAs
weredecreasedinmetastasispronesamples.Thus,ourdatareinforce
the role of p53 as a potential regulator of this miRNA family.
We found an important deregulation of miRNAs in tumours
affecting those involved in epidermal development
32,33 and meta-
stasis
71,72. However, upon highly restrictive analyses, few miRNAs
were associated with the spindle morphology of the tumours.
Among them, we observed a good correlation with increased miR-
21expressioninundifferentiatedSpCCsamplesandincreasedmeta-
static potential. This is in agreement with the reported increased
miR-21 expression in human tumours bearing mutated TP53 and
displaying distant metastasis
39. Our data are also in agreement with
thereducedsusceptibilitytochemicalcarcinogenesisinskinduetoin
vivo loss of miR-21
73. The functions of miR-21 in oncogenesis and
metastasis have been associated with its ability to target multiple
tumour suppressors, including PTEN and Spry1/2 leading to
increased Akt and MAPK activities
41,42,73. In agreement, we could
correlate such increased Aktand MAPK activities with the increased
expression of miR-21 and EMT processes (Fig2). Notably, increased
expressionofmiR-21wasunabletopromotetransformationorEMT
in immortalized keratinocytes (Supp Fig2), but contributed to the
acquisition of metastatic properties in otherwise poorly metastatic
transformed PB cells and promoted poorly differentiated tumours.
This finding is in agreement with our previous data showing that
Figure 7 | miR-21 expression in human lung cancers. (a-c) Box plots showing the miR-21 expression in human lung carcinomas
63 according to TP53
gene status (a), KRAS gene status (b) or the presence or absence of distant metastasis (c). (d) Correlation between miR-21 levels and the expression of
SPRY2 or PTEN genes in human lung cancer samples
63.
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angiogenesis
44,45. In agreement, the in vivo elimination of miR-21
does not promote tumour development but confers increased sens-
itivity to chemical carcinogenesis protocols
73.
In summary, it is conceivable that other mechanisms could con-
tribute to the metastatic capacities of p53-deficient tumours. TGFb
and p53 have been suggested as potential mechanisms for the dereg-
ulation of miRNAs
18,74, and these small non coding RNAs have been
widely involved in oncogenesis and in metastasis promotion
28,71,72.
Notably miR-21 can be induced by TGFb and contributes to
increased migration in HaCaT cells during wound healing
75. In this
regard, we found that overexpression of Snail, which is a target of
TGFb-mediated EMT
76, also induced miR-21 although to a mod-
erate level. Of note, we also found that S6 phosphorylation, a well
known effect of mTOR activation, was increased in the undifferenti-
ated,metastasis-prone, primarytumours.Thiscouldbeattributed to
the loss of p53 functions
49 and can contribute to increased TGFb
activity in tumours
77-79. The possible cooperative roles between
TGFb signalling and miR-21 in EMT as well as the possible roles
of TGFb in inducing this miRNA would deserve future research.
Regarding the possible mechanisms leading tothe upregulation of
miR-21 expression, it has been shown that miR-21 expression is
induced by activated Stat3
53 and by PI3K- and Erk-dependent sig-
nalling
80. Notably, Stat3 and mTOR pathways are activated by p53
loss
49-52,81 and are also functionally interconnected
82,83. We observed
that tumours showing increased activity of mTOR and/or Stat3 also
displayedincreasedmiR-21levels.Theuseofinhibitorsagainstthese
twopathwaysindicatedthattheinductionofmiR-21couldbeattrib-
uted, in this system, to their coordinated function. This observation
opens the possibility that these inhibitors could be considered of
particular relevance to prevent metastatic spreading in the mouse
tumours, which undoubtedly merits future investigation.
Our findings, demonstrating that miR-21 expression was elevated
in human lung tumours bearing mutated TP53 and displaying dis-
tant metastasis, are of a particular relevance. This observation is in
agreementwithpreviousreportsindicatingitsroleinlungcancer
58,59.
Here, using a series of molecularly characterized human tumours we
could establish that such increased expression is correlated with
decreased expression of SPRY2 and PTEN. Therefore the oncogenic
and metastatic-prone activities of miR-21 are not exclusively assoc-
iated with SCCs, but could be a more generalized tumoural process.
The validation of the molecular events contributing to the increased
expression of miR-21 in vivo are also of a particular relevance in the
design of potential therapies against metastatic spreading of primary
human lung tumours showing increased miR-21 expression.
Methods
Mouse and Histological procedures. Mouse models have been previously
described
20. Histological analyses were performed as previously reported in formalin
fixed paraffin embedded samples
20,24,84. For immunohistochemistry, high
temperature antigen unmasking technique (10-minute microwaving of slides in
0.01M citrate buffer) was used after deparaffinization to enhance the staining.
Sections were then incubated with 5% horse serum for 30 minutes to block the Fc
receptor in tissue, and then washed three times with sterile PBS (pH 7.5) prior to
incubation with the appropriate primary antibodies diluted in PBS/BSA. Antibodies
are listed on Supplementary Table 2. Biotin-conjugated secondary antibodies were
purchased from Jackson ImmunoResearch and used at 1/5000 dilution. For IHC,
signal was amplified using avidin-peroxidase (ABC elite kit Vector) and peroxidase
wasvisualizedusingdiaminobenzidineasasubstrate(DABkitVector).Controlslides
were obtained by replacing primary antibodies with PBS (data not shown). All the
animal experiments were approved by the Animal Ethical Committee (CEEA) and
conducted in compliance with Centro de Investigaciones Energe ´ticas,
Medioambientales y Tecnolo ´gicas (CIEMAT) guidelines.
CellcultureandChemicals.HaCaTandPBcellswereculturedinDMEMcontaining
10% FBS. Transfection experiments were performed as described
85 using plasmids
codingforhumanmiR-21(NKIlibrary
86)andSnail
87.Theselectionofthetransfected
cells was performed for at least 15 days in appropriate antibiotic containing medium
and40-60pooledcloneswereused.Migrationandinvasivenessweremonitoredusing
boyden chambers (BD-Biosciences) following the manufacturer’s recommendations.
Tumour cells were obtained from a primary tumour of an Rb
DEC; p53
DEC mouse
bearing lung metastasis upon trypsin digestion and disaggregation. Tumour cells
were grown as reported for wild type mouse epidermal keratinocytes
22. The non
transformed immortalized CoCa keratinocyte cell line
56 was cultured in CnT7
(CellnTech Genycell). miR-ZIP-21 was purchased from System Bioscience and
transfected in the tumour cells using Fugene (Roche). Indirect immunofluorescence
including BrdU detection was performed as previously described
85,88,89.
Pharmacological inhibition was performed incubating cultures for 48 hours in the
presence of Rapamycin (50 nM) and/or Tyrphostin AG940 (100 mM) (Sigma).
Positron Emission Tomography (PET). In vivo imaging by positron emission
tomography using 2-[
18F]Fluoro-2-deoxy-d-glucose (FDG), as tracer was performed
aspreviouslyreported
84.Imagesweretakeninanaxialplaneavoidingbrainandheart
to eliminate the possible background due to the high incorporation of FDG in these
organs.
External microarray datasets of human cancer. To stratify human lung cancer
patients according the miR-21 expression, two different external datasets
61,62 were
used.Todeterminethepossiblegenomicsimilaritiesbetweenhumanlungandmouse
p53-deficientepidermaltumours,wefollowedourpreviouslyreportedapproach
26.In
particular, we determined whether a 20-gene signature characteristic of mouse p53-
deficient tumours, which can identify human tumours with poor outcome from
breast cancer, astrocytoma and multiple myeloma
26, can also help to determine the
prognosis ofhuman lungcancer patients. Tothis,we obtained the corresponding 20-
gene score in each human tumour sample from a comprehensive genomic study of
human lung adenocarcinomas downloaded from GEO
57. This allows the
classificationofthesamplesinthreegroupsdependingonthisscore
26andanalyzethe
association of these clusters of patients with disease specific survival.
Gene expression of human lung tumors used to monitor microRNA expression
have been previously reported
63. Tissues were provided by the CNIO Tumour Bank
Network, in collaboration with different Spanish hospitals. The study was approved
by the corresponding institutional review boards and ethics committees, and
informed consent was obtained from each patient.
Microarray analyses. The microarray analysis using Affymetrix mouse gene chip
430A of total RNA extracted from tumours has been previously reported
26. The
microRNA analysis was performed using miRCURY LNA
TM v 11.0 platform. This
containsmorethan1700captureprobes,coveringallhuman,mouseandratmiRNAs
annotated in miRBase 11.0, as well as all viral microRNAs. In addition, this array
contains capture probes for 435 new miRPlus
TM human miRNAs. The probes
allowing classification between normal and tumoural samples was performed by
sequential SAM (FDR q,0.01) and t Test (Bonferroni corrected p,0.01) analyses.
The supervised analysis discriminating SCC and SpCC was performed in a similar
manner using the previous dataset.
Western blot. Ground mortar obtained extracts from tumour or skin samples, or
pelleted keratinocytes were lysed by freeze-thawing cycles in lysis buffer (200 mM
HEPES pH 7’9, 25% glycerol, 400 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mg/mL
aprotinin, 1 mg/mL leupeptin, 1 mM PMSF, 20 mM NaF, 1 mM NaPPi, 1 mM
Na3VO4, 2.5 mM DTT), and centrifuged to obtain supernatant containing total
protein.35mgprotein persamplewereresolved inSDS-PAGE gelsandtransferred to
nitrocellulose membranes (Amersham). Membranes were blocked with 5% non-fat
milk diluted in TBS and incubated with the appropriate antibodies diluted in TBS-T
0.5%BSA.SecondaryantibodieswerepurchasedfromJacksonImmunoResearchand
used at 1/5000. Super Signal West Pico Chemiluminscence Substrate (Pierce) was
used according to the manufacturer’s recommendations to visualize the bands. In all
cases Actin was used for loading control. The antibodies are as follows Actin (Santa
Cruz sc-1616 diluted 1/500), Akt (Santa Cruz sc-1619 diluted 1/500), E-cadherin
(Transduction Lab 610182, diluted 1/2500) Erk (Santa Cruz sc-154, diluted 1/500)
FOXC2(AbCam5060diluted1/500)KeratinK5(CovancePRB-160P,diluted1/500),
p53 (NovoCastra NCL-p53-CM5p, diluted 1/500), P-Akt (ser 473) (Cell Signaling
4058S,diluted 1/200) P-Erk (Santa Cruzsc-7383, diluted 1/200), P-S6 (Cell Signaling
2211, diluted 1/250), P-Stat3(Tyr 705) (Cell Signaling 9131, diluted 1/250), PTEN
(Santa Cruz sc-6818, diluted 1/500), Snail (AbCam 17732, diluted 1/1000), Sprouty 2
(SantaCruzsc-30049,diluted1/500)Stat3(CellSignaling4904,diluted1/500),Twist
(AbCam ab50581, diluted 1/5000 and Abnova H00007291-M01, diluted 1/300)
Vimentin (Biogenex, diluted 1/200), Zeb1 (Santa Cruz 10572, diluted 1/100), anti
BrdU (AbCam ab6326, diluted 1/100; and Roche 1170376, diluted 1/100), Dicer
(AbCam ab14201, diluted 1/100), Drosha (AbCam ab12286, diluted 1/100) and
DGCR8 (AbCam ab36865, diluted 1/200).
Quantitative real-time PCR from mRNA and miRNA. Purification of total RNA
including miRNA was done using the miRNeasy Mini Kit (Qiagen). RNA integrity
wastestedusingBioanalyzer(Agilent).Forgeneexpression,reversetranscriptionwas
done with the OmniscriptH Reverse Transcription kit (Qiagen) using oligo-dT
primers. Real-time PCR was performed using gene specific primers (Supplementary
Table4)andtheSYBRGreensystem(AppliedBiosystems).b-glucuronidase(GUSB)
wasusedasnormalizing,housekeepinggene.TaqManHMicroRNAAssays (Applied
Biosystems)wereusedtoquantifymiRNAsinsamplesaccordingtothemanufacturer
instructions with the TaqManH Universal PCR Master Mix reagent kit (Applied
Biosystems). Normalization was performed using U6 as housekeeping small RNA.
qRT-PCR formRNA andmiRNA wasperformedin anABI7500fastReal-Time PCR
System.
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GUS B:
Forward 59… GAGGATCAACAGTGCCCATT…39
Reverse 59… CAGCCTCAAAGGGGAGGT…39
Murine Snai1:
Forward 59…CACCTCCAGACCCACTCAGAT…39
Reverse 59…CCTGAGTGGGGTGGGAGC…39
COP-GFP:
Forward 59…CGGCTTCTACCACTTCGGC…3
Reverse 59…TTGTTGATGGCGTGCAGGA…39
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